Extracorporeal Shock Wave Therapy With a Wide Focus Probe for the Treatment of Erectile Dysfunction
Study Details
Study Description
Brief Summary
Low intensity shockwaves (1/10 the ones used in Lithotripsy) are delivered to the penile tissue. Shockwaves are created by a special generator and are focused using a specially designed shockwave applicator apparatus. The shockwaves are delivered through the applicator covering the corpora cavernosa of the penis. In previous studies the investigators used a medium focused probe and in this study the investigators are evaluating results of this therapy using a wider focus probe in the aim of improving results of treatment.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Treatment LI-ESWT Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites. |
Device: Low intensity shock waves
1500 shocks, Energy Density - 0.09 mJ/mm2
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Change in IIEF-ED Domain Questionaire Score > 5 points is considered treatment success [13 weeks]
Secondary Outcome Measures
- Rigidity Score Questionaire- an increase by at least 1 point is considered success [13 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
ED of more than 6 months
-
At least 50% unsuccessful to attempt sexual intercourse for 4 times at 4 different days
-
Positive response to PDE-5 inhibitors
-
IIEF-5 domain score of 12-20 denoting mild to severe ED
-
Non-Neurological pathology
-
Stable heterosexual relationship for more than 3 months
Exclusion Criteria:
-
NPT - normal/flat
-
Prior prostatectomy surgery
-
Any cause of ED other than vascular related
-
Any unstable medical, psychiatric, spinal cord injury, penile anatomical abnormalities
-
Clinically significant chronic hematological disease
-
Cardiovascular conditions that prevent sexual activity
-
History of heart attack, stroke or life-threatening arrhythmia within the prior 6 months.
-
Cancer within the past 5 years.
-
Anti-androgens, oral or injectable androgens
-
Use of any treatment for ED within 7 days of screening including oral medications, vacuum devices, constrictive devices, injections or urethral suppositories
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Rambam Medical Center | Haifa | Israel |
Sponsors and Collaborators
- Rambam Health Care Campus
Investigators
- Principal Investigator: Ilan Gruenwald, MD, Rambam Health Care Campus
- Study Director: Yoram Vardi, Prof., Rambam Health Care Campus
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 0571-10-RMB